interleukin-18 dendritic cell vaccine

**Interleukin-18 dendritic cell vaccine** is an autologous, cell-based immunotherapy comprising patient-derived dendritic cells that are genetically modified to express interleukin-18 (IL-18) and often pulsed with tumor lysates. IL-18 is a pro-inflammatory cytokine that enhances T cell and natural killer (NK) cell activation, thereby promoting the generation of potent, tumor-specific cytotoxic lymphocyte responses. In preclinical studies, such vaccines have demonstrated significant antitumor effects through increased Th1 cytokine production—especially interferon-gamma (IFN-γ)—and cytotoxic T cell activity, resulting in improved survival in murine models of cancer. The approach is under preclinical or early clinical investigation primarily for solid tumors such as pancreatic carcinoma, with the method aiming to boost anti-tumor immunity while minimizing systemic cytokine toxicity by targeting expression to antigen-presenting dendritic cells[1][2].

Other names

IL-18 DC vaccineIL18 DC vaccineIL 18 DC vaccineinterleukin-18 gene-modified dendritic cell vaccineinterleukin18 gene-modified dendritic cell vaccineinterleukin 18 gene-modified dendritic cell vaccineIL-18 gene-transfected DC vaccineIL18 gene-transfected DC vaccineIL 18 gene-transfected DC vaccine